Next Article in Journal
From Mosquito Bites to Sexual Transmission: Evaluating Mouse Models of Zika Virus Infection
Previous Article in Journal
Nuclear Import of HIV-1
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection

1
School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China
2
Key Laboratory of Tropical Disease Control, Sun Yat-sen University, Ministry of Education, Guangzhou 510080, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Viruses 2021, 13(11), 2243; https://doi.org/10.3390/v13112243
Submission received: 14 October 2021 / Revised: 31 October 2021 / Accepted: 2 November 2021 / Published: 8 November 2021
(This article belongs to the Section SARS-CoV-2 and COVID-19)

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells mainly by the angiotensin converting enzyme 2 (ACE2) receptor, which can recognize the spike (S) protein by its extracellular domain. Previously, recombinant soluble ACE2 (sACE2) has been clinically used as a therapeutic treatment for cardiovascular diseases. Recent data demonstrated that sACE2 can also be exploited as a decoy to effectively inhibit the cell entry of SARS-CoV-2, through blocking SARS-CoV-2 binding to membrane-anchored ACE2. In this study, we summarized the current findings on the optimized sACE2-based strategies as a therapeutic agent, including Fc fusion to prolong the half-life of sACE2, deep mutagenesis to create high-affinity decoys for SARS-CoV-2, or designing the truncated functional fragments to enhance its safety, among others. Considering that COVID-19 patients are often accompanied by manifestations of cardiovascular complications, we think that administration of sACE2 in COVID-19 patients may be a promising therapeutic strategy to simultaneously treat both cardiovascular diseases and SARS-CoV-2 infection. This review would provide insights for the development of novel therapeutic agents against the COVID-19 pandemic.
Keywords: SARS-CoV-2; ACE2 receptor; soluble ACE2; optimized sACE2; therapeutic agent SARS-CoV-2; ACE2 receptor; soluble ACE2; optimized sACE2; therapeutic agent

Share and Cite

MDPI and ACS Style

Feng, F.; Chen, J.; Zhao, J.; Li, Y.; Li, M.; Sun, C. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Viruses 2021, 13, 2243. https://doi.org/10.3390/v13112243

AMA Style

Feng F, Chen J, Zhao J, Li Y, Li M, Sun C. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Viruses. 2021; 13(11):2243. https://doi.org/10.3390/v13112243

Chicago/Turabian Style

Feng, Fengling, Jiaoshan Chen, Jin Zhao, Yanjun Li, Minchao Li, and Caijun Sun. 2021. "Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection" Viruses 13, no. 11: 2243. https://doi.org/10.3390/v13112243

APA Style

Feng, F., Chen, J., Zhao, J., Li, Y., Li, M., & Sun, C. (2021). Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Viruses, 13(11), 2243. https://doi.org/10.3390/v13112243

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop